ProMeris Duo

RSS

metaflumizone / amitraz

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for ProMeris Duo has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 13/07/2015

Authorisation details

Product details
Name
ProMeris Duo
Agency product number
EMEA/V/C/000108
Active substance
metaflumizone / amitraz
International non-proprietary name (INN) or common name
metaflumizone / amitraz
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53AD51
Publication details
Marketing-authorisation holder
Pfizer Limited 
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
19/12/2006
Contact address
Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Product information

08/07/2015 ProMeris Duo - EMEA/V/C/000108 - IB/0011

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), and ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs.

The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Assessment history

How useful was this page?

Add your rating